摘要
中药单体如酚类(丹酚酸B、姜黄素、白藜芦醇)、萜类(毛喉素、罗汉果皂苷Ⅳ、龙胆苦苷等)、黄酮类(原花青素B2、淫羊藿苷、汉黄芩素等)、生物碱类(川芎嗪、黄连素)及补肾化瘀方、慈菇消脂方、茵陈三甲散、抗纤软肝颗粒等中药复方或中成药可通过抑制Hedgehog信号通路调控肝星状细胞活化、调控肝星状细胞增殖与凋亡、抑制肝脏炎症反应、抑制肝窦毛细血管化等途径发挥防治肝纤维化的目的,具有多层次、多靶点、多环节的独特优势。
Traditional Chinese medicine monomers such as phenols(salvianolic acid B,curcumin and resveratrol),terpenoids(forskolin,mogrosideⅥ,gentianoside,etc.),flavonoids(proanthocyanidin B2,icariin,wogonin,etc.),alkaloids(ligustrazine and berberine),and traditional Chinese medicine compounds or proprietary Chinese medicines,such as Bushen Huayu Decoction(补肾化瘀方),Cigu Xiaozhi Decoction(慈菇消脂方),Yinchen Sanjia Powder(茵陈三甲散)and Kangxian Ruangan Granule(抗纤软肝颗粒)can regulate the activation of hepatic stellate cells,regulate the proliferation and apoptosis of hepatic stellate cells,inhibit liver inflammation,and inhibit hepatic sinusoidal capillarization by inhibiting the Hedgehog signaling pathway.It has the unique advantages of multi-level,multi-target and multi-link.
作者
宗路路
罗磊
孙晓娜
陈乾
王宇亮
ZONG Lulu;LUO Lei;SUN Xiaona;CHEN Qian;WANG Yuliang(Henan University of Chinese Medicine,Zhengzhou Henan 450006,China;Henan Provincial Hospital of Traditional Chinese Medicine/The Second Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou Henan 450002,China)
出处
《中医药导报》
2025年第2期99-106,共8页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金青年项目(82305074,82104833)
河南省中医药传承与创新人才工程(仲景工程)(院行〔2022〕26号)。
